These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Montouris G; Abou-Khalil B Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial. Machado RA; García VF; Astencio AG; Cuartas VB Seizure; 2013 Dec; 22(10):846-55. PubMed ID: 23916525 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Chowdhury A; Brodie MJ Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554 [TBL] [Abstract][Full Text] [Related]
7. Epilepsy with myoclonic absences. Surve TY; Mittal G; Khadse SS; Khanna SA Indian J Pediatr; 2006 Feb; 73(2):151-2. PubMed ID: 16514226 [TBL] [Abstract][Full Text] [Related]
8. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366 [TBL] [Abstract][Full Text] [Related]